Taipei Medical University Institutional Repository:Item 987654321/58497
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 45069/58245 (77%)
Visitors : 2369168      Online Users : 170
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://libir.tmu.edu.tw/handle/987654321/58497


    Title: 開發新型雙功能抗體以強化T細胞毒殺高表現表皮生長因子受體三陰性乳癌之功效
    Development of novel bispecific antibody to enhance therapeutic effect of T cells against EGFR-expressing triple negative breast cancer
    Authors: 李依庭
    Lee, Yi-Ting
    Contributors: 臨床藥物基因體學暨蛋白質體學碩士學位學程
    莊國祥
    Keywords: 三陰性乳腺癌(Triple Negative Breast Cancer);MDA-MB-231;新型雙功能抗體;PBMC(Peripheral Blood Mononuclear Cell);T 細胞;雙功能抗體培育之T 細胞(Antitumoe Arm-T cell)平台
    Triple Negative Breast Cancer (TNBC);bispecific antibody (BsAbs);efficiently differentiate, highly expand;Armed-T cells;MDA-MB-231
    Date: 2018-12-28
    Issue Date: 2020-01-20 13:05:46 (UTC+8)
    Abstract: 三陰性乳癌(Triple Negative Breast Cancer)於臨床表徵為ER (Estrogen receptor)、PR (Progesterone receptor)以及HER2 (Human Epidermal Growth Factor Receptor 2) 皆呈陰性之乳癌種類1,2,目前仍以化學療法為主要治療方式,其五年存活率僅62%。為提供三陰性乳癌更佳之治療,本實驗室開發新型雙功能抗體培育T細胞療法平台(Anti-tumor Armed-T cell),於活體外培育周邊血單核球細胞 (Peripheral Blood Mononuclear Cell,PBMC)過程添加新型雙功能抗體,使周邊血單核球細胞可於10天內快速增殖、分化並轉變為具抗原專一性之CD3+CD8+ T細胞(Anti-tumor Armed-T cell),以提升T細胞對腫瘤專一性毒殺。研究結果顯示,我們利用蛋白質工程技術成功建構出新型雙功能抗體,並藉流式細胞儀確認其與三陰性乳癌細胞(MDA-MB-231,EGFR+)以及T細胞(CD3+)之雙邊結合能力,並確認T細胞增殖、分化為CD3+CD8+ T細胞之效果,且於活體外證實Anti-tumor Arm-T cell細胞具專一性快速辨認,並釋放細胞激素/毒素,以提升毒殺並抑制三陰性乳癌細胞(MDA-MB-231,EGFR+)生長之能力。本研究開發一全新T細胞療法治療策略,藉由新型anti-EGFR/anti-CD3雙功能抗體一步驟武裝、分化並增殖成為具腫瘤專一性之T細胞。
    Triple Negative Breast Cancer (TNBC) is corresponded to 15 to 20 % of all breast cancer diagnosis in women. Anthracycline and taxane-based chemotherapy are the mainly treatment for TNBC in clinical; however, the lack of effective target led to worse 5-year overall and disease-free survival rate with 62% and 57.5%. Therefore, novel treatment for TNBC is urgent needed. In our previous study, we have developed the novel ex vivo bispecific antibody (BsAb) cultured platform for T cells (Anti-tumor Arm-T cell), in which T cells were cultured with BsAb that is combined with anti-tumor antibody to anti-CD3 antibody, making Peripheral Blood Mononuclear Cells (PBMCs) have the ability to differentiate efficiently, highly expand to Anti-tumor Arm-T cell with the selective function to eliminate cancer cells in the same time. We successfully construct the novel BsAb and ensure the bispecific function by TNBC cell line (MDA-MB-231,EGFR+)and T cell (CD3+).Moreover, Anti-tumor Arm-T cell could rapidly recognize MDA-MB-231 as soon as possible and release cytokines to elevate the ability to eliminate tumor cells in vitro and in vivo study. To summarize, our study provides a novel adoptive T cell therapy (Anti-tumor Arm-T cell) with rapid differentiating, expanding, and arming human T cells by adding novel BsAb into human PBMC culture medium and enhancing the ability of T cells to target the TNBC.
    Description: 碩士
    指導教授:莊國祥
    委員:鄒協成
    委員:卓爾婕
    Data Type: thesis
    Appears in Collections:[Master Program for Clinical Pharmacogenomics and Pharmacoproteomics] Dissertations/Theses

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML69View/Open


    All items in TMUIR are protected by copyright, with all rights reserved.


    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback